Clinical Trial Update: Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 study evaluating bendamustine, bortezomib, and dexamethasone (BBD) as first-line therapy for multiple myeloma in pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Treanda (Bendamustine)
• Velcade (bortezomib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-03-28